{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:13:31Z","timestamp":1753892011866,"version":"3.41.2"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:00:00Z","timestamp":1726185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010801","name":"Xunta de Galicia","doi-asserted-by":"publisher","award":["IN845D 2020\/01 IN606A 2022\/048"],"award-info":[{"award-number":["IN845D 2020\/01 IN606A 2022\/048"]}],"id":[{"id":"10.13039\/501100010801","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>In the context of the cytokine storm the takes place in severe COVID-19 patients, the <jats:italic>Interleukin 6<\/jats:italic> (<jats:italic>IL6<\/jats:italic>) pathway emerges as one of the key pathways involved in the pathogenesis of this hyperinflammatory state. The strategy of blocking the inflammatory storm by targeting the <jats:italic>IL6<\/jats:italic> is a promising therapy to mitigate mortality. The use of Tocilizumab was recommended by the World Health Organization (WHO) to treat severe COVID-19 patients. However, the efficacy of Tocilizumab is variable. We hypothesize that the genetic background could be behind the efficacy of Tocilizumab in terms of mortality.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We performed a targeted-next generation sequencing of 287 genes, of which 264 belong to a community panel of ThermoFisher for the study of genetic causes of primary immunodeficiency disorders, and 23 additional genes mostly related to inflammation, not included in the original community panel. This panel was sequenced in an initial cohort of 425 COVID-19 patients, of which 232 were treated with Tocilizumab and standard therapy, and 193 with standard therapy only. Selected genetic variants were genotyped by single base extension in additional 245 patients (95 treated with Tocilizumab and 150 non-treated with Tocilizumab). Appropriate statistical analyses and internal validation, including logistic regression models, with the interaction between Tocilizumab and genetic variants, were applied to assess the impact of these genetic variants in the efficacy of Tocilizumab in terms of mortality.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Age (<jats:italic>p<\/jats:italic> &amp;lt; 0.001) and cardiovascular disease (<jats:italic>p<\/jats:italic> &amp;lt; 0.001) are risk factors for mortality in COVID-19 patients. The presence of GG and TT genotypes at <jats:italic>IL10R\u03b2<\/jats:italic> (rs2834167) and <jats:italic>IL1\u03b2<\/jats:italic> (rs1143633) genes significantly associates with a reduced risk of mortality in patients treated with Tocilizumab (OR = 0.111; 95%CI = 0.015\u20130.829; <jats:italic>p<\/jats:italic> = 0.010 and OR = 0.378; 95%CI = 0.154\u20130.924; <jats:italic>p<\/jats:italic> = 0.028 respectively). The presence of CC genotype at <jats:italic>IL1RN<\/jats:italic> (rs2234679) significantly associates with an increased risk of mortality, but only in patients not treated with Tocilizumab (OR = 3.200; 95%CI = 1.512\u20136.771; <jats:italic>p<\/jats:italic> = 0.002). Exhaustive internal validation using a bootstrap method (B = 500 replicates) validated the accuracy of the predictive models.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We developed a series of predictive models based on three genotypes in genes with a strong implication in the etiopathogenesis of COVID-19 disease capable of predicting the risk of mortality in patients treated with Tocilizumab.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1426826","type":"journal-article","created":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T12:59:35Z","timestamp":1726232375000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["An exploratory analysis of associations of genetic variation with the efficacy of tocilizumab in severe COVID-19 patients. A pharmacogenetic study based on next-generation sequencing"],"prefix":"10.3389","volume":"15","author":[{"given":"Alejandro","family":"Dur\u00e1n-Sotuela","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"V\u00e1zquez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Rela\u00f1o-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanesa","family":"Balboa-Barreiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Fern\u00e1ndez-Tajes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco J.","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"Rego-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s10787-022-01114-8","article-title":"The effect of ramatroban on cytokine and thrombotic storms in Covid-19","volume":"31","author":"Al-Kuraishy","year":"2023","journal-title":"Inflammopharmacology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e838","DOI":"10.1002\/iid3.838","article-title":"Mixed storm in SARS-CoV-2 infection: a narrative review and new term in the Covid-19 era","volume":"11","author":"Alomair","year":"2023","journal-title":"Immun. Inflamm. Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"354","DOI":"10.3390\/ijms25010354","article-title":"An update on SARS-CoV-2 clinical trial results-what we can learn for the next pandemic","volume":"25","author":"Arman","year":"2023","journal-title":"Int. J. Mol. Sci."},{"volume-title":"Interleukin-1 receptor antagonist gene (medRxiv","year":"2023","author":"Attur","key":"B4"},{"key":"B5","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.jaci.2022.05.029","article-title":"Spontaneous NLRP3 inflammasome-driven IL-1-\u03b2 secretion is induced in severe COVID-19 patients and responds to anakinra treatment","volume":"150","author":"Bertoni","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.4081\/monaldi.2022.2136","article-title":"Tocilizumab for COVID-19: a systematic review and meta-analysis of randomized controlled trials","volume":"92","author":"Boppana","year":"2022","journal-title":"Monaldi Arch. Chest Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/s41591-020-1051-9","article-title":"An inflammatory cytokine signature predicts COVID-19 severity and survival","volume":"26","author":"Del Valle","year":"2020","journal-title":"Nat. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/nrd3800","article-title":"Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases","volume":"11","author":"Dinarello","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"B9","doi-asserted-by":"publisher","first-page":"541","DOI":"10.2217\/bmm-2020-0422","article-title":"Utility of inflammatory biomarkers in patients with COVID-19 infections: Bahrain experience","volume":"15","author":"Farid","year":"2021","journal-title":"Biomark. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1038\/ng.3985","article-title":"Shared genetic origin of asthma, hay fever and eczema elucidates allergic disease biology","volume":"49","author":"Ferreira","year":"2017","journal-title":"Nat. Genet."},{"key":"B11","doi-asserted-by":"publisher","first-page":"9148","DOI":"10.1073\/pnas.0602800103","article-title":"Class II cytokine receptor gene cluster is a major locus for hepatitis B persistence","volume":"103","author":"Frodsham","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B12","doi-asserted-by":"publisher","first-page":"CD013881","DOI":"10.1002\/14651858.CD013881.pub2","article-title":"Interleukin-6 blocking agents for treating COVID-19: a living systematic review","volume":"6","author":"Ghosn","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e0270668","DOI":"10.1371\/journal.pone.0270668","article-title":"Association between tocilizumab, sarilumab and all-cause mortality at 28 days in hospitalised patients with COVID-19: a network meta-analysis","volume":"17","author":"Godolphin","year":"2022","journal-title":"PLoS One"},{"key":"B14","doi-asserted-by":"publisher","first-page":"11292","DOI":"10.3390\/ijms241411292","article-title":"Association of IL10RA, IL10RB, and IL22RA polymorphisms\/haplotypes with susceptibility to and clinical manifestations of SLE","volume":"24","author":"Grk","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.bbrc.2008.06.054","article-title":"Association of IL-10 receptor 2 (IL10RB) SNP with systemic sclerosis","volume":"373","author":"Hikami","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B16","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"102567","DOI":"10.1016\/j.autrev.2020.102567","article-title":"Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions","volume":"19","author":"Jamilloux","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"B18","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1002\/hon.2322","article-title":"Polymorphism of IL-10 receptor \u03b2 affects the prognosis of multiple myeloma patients treated with thalidomide and\/or bortezomib","volume":"35","author":"Kasamatsu","year":"2017","journal-title":"Hematol. Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/imr.12620","article-title":"Interleukin 1 gene polymorphism and susceptibility to disease","volume":"281","author":"Khazim","year":"2018","journal-title":"Immunol. Rev."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1007\/s11684-023-1044-4","article-title":"Cytokine storm and translating IL-6 biology into effective treatments for COVID-19","volume":"17","author":"Li","year":"2023","journal-title":"Front. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3390\/genes13020291","article-title":"Association of interleukin genes IL10 and IL10RB with parameters of overweight in military students","volume":"13","author":"Maculewicz","year":"2022","journal-title":"Genes (Basel)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"16556","DOI":"10.3390\/ijms242316556","article-title":"NLRP3 inflammasome involvement in heart, liver, and lung diseases-A lesson from cytokine storm syndrome","volume":"24","author":"Napodano","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s00296-015-3379-x","article-title":"Levels of interleukin-1 beta can predict response to tocilizumab therapy in rheumatoid arthritis: the PETITE (predictors of effectiveness of tocilizumab therapy) study","volume":"36","author":"Okano","year":"2016","journal-title":"Rheumatol. Int."},{"key":"B24","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1146\/annurev-immunol-031210-101312","article-title":"Regulation and functions of the IL-10 family of cytokines in inflammation and disease","volume":"29","author":"Ouyang","year":"2011","journal-title":"Annu. Rev. Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1007\/s11033-012-2232-5","article-title":"Association between IL10, IL10RA, and IL10RB SNPs and ischemic stroke with hypertension in Korean population","volume":"40","author":"Park","year":"2013","journal-title":"Mol. Biol. Rep."},{"key":"B26","doi-asserted-by":"publisher","first-page":"557","DOI":"10.18632\/aging.203834","article-title":"Association between tocilizumab treatment and clinical outcomes of COVID-19 patients: a systematic review and meta-analysis","volume":"14","author":"Peng","year":"2022","journal-title":"Aging (Albany NY)"},{"key":"B27","doi-asserted-by":"publisher","first-page":"102276","DOI":"10.1016\/j.pmedr.2023.102276","article-title":"Efficacy and safety of interleukin-6 receptor antagonists in adult patients admitted to intensive care unit with COVID-19: a systematic review and meta-analysis of randomized controlled trials","volume":"34","author":"Peng","year":"2023","journal-title":"Prev. Med. Rep."},{"key":"B28","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1001\/jama.2020.1097","article-title":"The novel coronavirus originating in wuhan, China: challenges for global health governance","volume":"323","author":"Phelan","year":"2020","journal-title":"JAMA"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e0269368","DOI":"10.1371\/journal.pone.0269368","article-title":"Efficacy and harms of tocilizumab for the treatment of COVID-19 patients: a systematic review and meta-analysis","volume":"17","author":"Piscoya","year":"2022","journal-title":"PLoS One"},{"key":"B30","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1080\/08916934.2017.1412431","article-title":"High expression of interleukine-1 receptor antagonist in rheumatoid arthritis: association with IL1RN*2\/2 genotype","volume":"50","author":"Ram\u00edrez-P\u00e9rez","year":"2017","journal-title":"Autoimmunity"},{"key":"B31","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1007\/s00134-020-05991-x","article-title":"Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China","volume":"46","author":"Ruan","year":"2020","journal-title":"Intensive Care Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1691\/ph.2016.6713","article-title":"Interleukin 6 receptor inhibitor tocilizumab suppresses cytokine expression, inflammasome activation and phagocytosis in a cell model of sepsis","volume":"71","author":"Sheng","year":"2016","journal-title":"Pharmazie"},{"key":"B33","doi-asserted-by":"publisher","first-page":"107597","DOI":"10.1016\/j.isci.2023.107597","article-title":"Transcriptomic and proteomic assessment of tocilizumab response in a randomized controlled trial of patients hospitalized with COVID-19","volume":"26","author":"Shivram","year":"2023","journal-title":"iScience"},{"key":"B34","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s42398-021-00204-7","article-title":"Novel coronavirus disease (COVID-19): origin, transmission through the environment, health effects, and mitigation strategies-a review","volume":"4","author":"Singh","year":"2021","journal-title":"Environ. Sustain (Singap)"},{"key":"B35","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s41512-022-00136-8","article-title":"Targeted validation: validating clinical prediction models in their intended population and setting","volume":"6","author":"Sperrin","year":"2022","journal-title":"Diagn Progn. Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e1474","DOI":"10.1002\/wrna.1474","article-title":"Genetic variants in mRNA untranslated regions","volume":"9","author":"Steri","year":"2018","journal-title":"Wiley Interdiscip. Rev. RNA."},{"key":"B37","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.jclinepi.2015.04.005","article-title":"Prediction models need appropriate internal, internal-external, and external validation","volume":"69","author":"Steyerberg","year":"2016","journal-title":"J. Clin. Epidemiol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1191\/096120399678847560","article-title":"Synergetic effect between interleukin-1 receptor antagonist allele (IL1RN*2) and MHC class II (DR17,DQ2) in determining susceptibility to systemic lupus erythematosus","volume":"8","author":"Tjernstr\u00f6m","year":"1999","journal-title":"Lupus"},{"key":"B39","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/j.1399-0039.2006.00704.x","article-title":"The different expression patterns of interleukin-1 receptor antagonist in systemic lupus erythematosus","volume":"68","author":"Tsai","year":"2006","journal-title":"Tissue Antigens"},{"key":"B40","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41577-020-0305-6","article-title":"In the eye of the COVID-19 cytokine storm","volume":"20","author":"Vaninov","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41525-022-00324-x","article-title":"A translational genomics approach identifies IL10RB as the top candidate gene target for COVID-19 susceptibility","volume":"7","author":"Voloudakis","year":"2022","journal-title":"NPJ Genom Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"e140289","DOI":"10.1172\/jci.insight.140289","article-title":"Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis","volume":"5","author":"Wilson","year":"2020","journal-title":"JCI Insight"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1080\/22221751.2022.2059405","article-title":"Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis","volume":"11","author":"Yu","year":"2022","journal-title":"Emerg. Microbes Infect."},{"key":"B44","doi-asserted-by":"publisher","first-page":"e139834","DOI":"10.1172\/jci.insight.139834","article-title":"Longitudinal COVID-19 profiling associates IL-1RA and IL-10 with disease severity and RANTES with mild disease","volume":"5","author":"Zhao","year":"2020","journal-title":"JCI Insight"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1426826\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T13:00:10Z","timestamp":1726232410000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1426826\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,13]]},"references-count":44,"alternative-id":["10.3389\/fphar.2024.1426826"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1426826","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2024,9,13]]},"article-number":"1426826"}}